Intelligent Pharmacy最新文献

{"title":"Microneedle technology- an insight into advancements, latest scholarly and patent data","authors":"Dhanvanth Kumar C ,&nbsp;Prakash S. Goudanavar ,&nbsp;Koteswara Rao GSN ,&nbsp;M Pradeep Kumar ,&nbsp;Kiran Kumar G B ,&nbsp;B. Ramesh ,&nbsp;N Raghavendra Naveen","doi":"10.1016/j.ipha.2023.09.008","DOIUrl":"10.1016/j.ipha.2023.09.008","url":null,"abstract":"<div><p>Microneedles (MN) have been used to deliver small molecular weight drugs, nucleotides, DNA, peptides, proteins, and even viruses that have been turned off. Over the past ten years, different kinds of MN have been made using several different production methods. Different kinds of materials have been used to make different shapes of microneedles. Using these MNs, different ways of putting drugs through the skin with microneedles have been tried. After a short introduction to microneedles for transdermal use, this review talks about the different kinds, how they are made, and recent improvements in MN delivery. In a separate part of this review, patents survey on MN using databases such as USPTO (United States Patent and Trademark Office), EPO (European Patent Office), and WIPO (World Intellectual Property Organization), etc. are discussed in detail. We talked about recent improvements to MN-based methods for getting drugs and vaccines to people. Because MN worked so well, there was a lot of interest in taking advantage of the opportunities, as patent data shows. With a current worldwide perspective, the current analysis confirms the overall evolution and unexplored areas of MN research and makes microneedle-based (trans)dermal drug delivery systems for effective therapeutic effects.</p></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"2 1","pages":"Pages 114-121"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949866X23000849/pdfft?md5=916393544ba1e2fcff19d0e27275ffa4&pid=1-s2.0-S2949866X23000849-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134915071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Co-Processed Excipients: Advances and Future Trends","authors":"Aditya Singh ,&nbsp;Shubhrat Maheshwari ,&nbsp;Vishal Kumar Vishwakarma ,&nbsp;Saad Mohammed","doi":"10.1016/j.ipha.2023.10.006","DOIUrl":"10.1016/j.ipha.2023.10.006","url":null,"abstract":"<div><p>This review provides a concise overview of recent advances and future perspectives in co-processed excipients which is characterized by their synergistic combinations have become pivotal in pharmaceutical formulations. This review delves in to the latest innovations manufacturing techniques and applications of co-processed excipients. Emphasis is placed on enhanced functionality, and improved performance and the potential for addressing formulation challenges. The abstract concludes by highlighting the future prospects and emerging trends in this dynamic field ,offering valuable insights for researchers and pharmaceutical professionals alike.</p></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"2 1","pages":"Pages 130-135"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949866X23000977/pdfft?md5=ad366e4eaec379fe0fa96fb3ffd5614c&pid=1-s2.0-S2949866X23000977-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136118390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development And Evaluation of topical liposomal preparation of Walnut oil and tamarind seed oil against ageing","authors":"Aditya Singh ,&nbsp;Vaseem Ahamad Ansari ,&nbsp;Md Faheem Haider ,&nbsp;Farogh Ahsan ,&nbsp;Tarique Mahmood ,&nbsp;Rufaida Wasim ,&nbsp;Shubhrat Maheshwari","doi":"10.1016/j.ipha.2023.09.007","DOIUrl":"10.1016/j.ipha.2023.09.007","url":null,"abstract":"<div><h3>Background</h3><p>Revamp of liposomal preparation inimical ageing by using a splendid treasure of herbal drugs includes non-prescription and prescription upshot. Liposomal therapy stands at the forefront of cutting-edge cosmeceutical innovation. It involves a sophisticated, bi-layered delivery system designed for the precise infusion of walnut oil and tamarind seed oil into the skin. This innovative approach effectively combats the signs of ageing, whether they are the result of a sedentary lifestyle or genetic factors within one's family history.</p></div><div><h3>Purpose</h3><p>The current study focuses on exploring the area of traditional systems of medicine in the field of pharmaceuticals to achieve the combined effect of walnut oil [F1] and tamarind seed oil [F2] in the form of liposomal preparation against ageing.</p></div><div><h3>Methods</h3><p>Liposomes of walnut oil and tamarind seed oil were developed by using a rotary vacuum evaporator, and microscopy of the formulated liposomes was done using a Digicam microscope, which provided a microscopic view that both formulated liposomes are spherical, but F1 liposomes are more dense and tactile than F2, and the F2 liposomal formulation has more vesicles than F1. <em>In-vitro</em> drug release studies of F1 and F2 were done by diffusion cells while using a dialysis membrane with buffer medium 6.8. Further characterization techniques like SEM and FTIR were used to investigate the size range with the clear shape of the particles and to obtain a clear peak that matched the pure drug, which shows that it has retained its pharmacological properties. The final step was directed towards the preparation of topical anti-ageing cream by combining F1 and F2 to obtain the synergistic effect, and the formulation cream was successfully visualised under a projection microscope at a magnification of 10x, which reveals that spherically droplet vacuoles are present with a soft texture and a creamy, whitish colour. Last but not least, a 14-day animal study was conducted on female Swiss mice from the authorised animal laboratory departmental animal house at Integral University. The studies were conducted in 3 groups: G1 was given saline as a control, G2 was given Olay as a topical application, and G3 was given the test cream. The anti-ageing potential of the formulated cream was evaluated by skin compliance studies using UV exposure.</p></div><div><h3>Results</h3><p>Walnut oil and tamarind seed oil-based liposomes were formulated after placebo selection, i.e., F1 and F2, and the microscopic view of F1 sphere-shaped vesicles is larger, brighter, and more dense than F2, and the sphere-shaped vesicles of F1 and F2 contain phospholipid bilayers composed of soyalecthin, which helps to deliver drugs at a specific site. The pH of two formulations, F1 and F2, was determined by storing them at different temperatures, 350°C and 450°C. The pH resultant values were in the range of 5.8 to 6.9, which means that the fo","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"2 1","pages":"Pages 28-39"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949866X23000837/pdfft?md5=7b55a02b1f6ddbcc0d42f8292f3fe0d1&pid=1-s2.0-S2949866X23000837-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135889877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronomodulated drug delivery systems for the treatment of hypertension: An overview","authors":"S. Sivaneswari ,&nbsp;K. Senthilkumaran ,&nbsp;R. Sambathkumar","doi":"10.1016/j.ipha.2023.10.001","DOIUrl":"10.1016/j.ipha.2023.10.001","url":null,"abstract":"<div><p>This review paper aims to provide an overview of chronomodulated drug delivery systems for the treatment of hypertension. Hypertension is a chronic medical condition that affects millions of people worldwide, and effective treatment is crucial to prevent complications such as heart disease and stroke. Chronomodulated drug delivery utilises the concept of circadian rhythms to optimise drug efficacy and minimise side effects. The paper examines various chronomodulated drug delivery approaches, including pulsatile, delayed-release, and chronopharmaceutical systems, highlighting their advantages and limitations. Furthermore, the potential future developments in this field are discussed, emphasising the importance of personalised medicine and the integration of wearable technology for real-time monitoring and drug administration. Overall, this review provides valuable insights into the potential of chronomodulated drug delivery systems for improving patient outcomes and minimising side effects. By utilising chronomodulated drug delivery approaches, healthcare professionals can ensure that medications are released at specific times when they are most effective, thereby maximising their therapeutic benefits. Pulsatile drug delivery systems, for example, can mimic the body's natural circadian rhythm, allowing for targeted drug release during periods of peak efficacy. Delayed-release systems, on the other hand, can help reduce side effects by delivering drugs to specific regions of the gastrointestinal tract where they are better tolerated.</p></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"2 1","pages":"Pages 155-160"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949866X23000874/pdfft?md5=2212ee84988098694fabd4d96bebf2b3&pid=1-s2.0-S2949866X23000874-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134937289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Synthesis and evaluation of antibacterial activity of novel 3-methyl-1H-indazole derivatives","authors":"Farrukh Shaikh,&nbsp;Muhammad Arif,&nbsp;Mohammad Khushtar,&nbsp;Md Nematullah,&nbsp;Md Azizur Rahman","doi":"10.1016/j.ipha.2023.09.003","DOIUrl":"10.1016/j.ipha.2023.09.003","url":null,"abstract":"<div><p>Aim of the study was designed to synthesize and evaluate antibacterial activity of novel heterocyclic compounds, 3-methyl-1<em>H</em>-indazole derivatives. The heterocyclic compounds, 3-methyl-1<em>H</em>-indazole derivatives (<strong>1a-1d</strong> and <strong>2a-2d</strong>) were synthesized; all of them characterized physically by melting point, R_f value, appearance &amp; solubility; and some of them characterized spectroscopically by IR and ¹H NMR spectroscopy. All the synthesized derivatives were evaluated for their antibacterial activity against both Gram positive bacteria, <em>Bacillus subtilis</em> and Gram negative bacteria, <em>Escherichia coli</em> by cup plate method using ciprofloxacin as a standard drug. All the synthesized heterocyclic compounds, 3-methyl-1<em>H</em>-indazole derivatives (<strong>1a-1d</strong> and <strong>2a-2d</strong>), had shown antibacterial activity against the <em>B. subtilis</em> and <em>E. coli</em>. Compound <strong>1d</strong> i.e., 1-(2-(piperidin-1-yl)ethan-1-oyl)-3-methyl-1<em>H</em>-indazole at the concentration of 300 ​μg/ml showed best antibacterial activity against the bacteria <em>B. subtilis</em> and <em>E. coli</em> as compared to standard drug, ciprofloxacin. The methodology for the synthesis of heterocyclic compounds, 3-methyl-1<em>H</em>-indazol-1-yl derivatives was simple as well as economical and gave better yield of the synthesized compounds. The compound, 1-(2-(piperidin-1-yl)ethan-1-oyl)-3-methyl-1<em>H</em>-indazole had shown best antibacterial activity against the bacteria <em>B. subtilis</em> and <em>E. coli</em>.</p></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"2 1","pages":"Pages 12-16"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949866X23000795/pdfft?md5=5973eaa3e4c5fa76b7dda7f4e227ed56&pid=1-s2.0-S2949866X23000795-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135889854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronomodulated drug delivery: Challenges, benefits, and future directions in asthma treatment","authors":"G. Manjunath ,&nbsp;S. Nirmala","doi":"10.1016/j.ipha.2023.07.002","DOIUrl":"10.1016/j.ipha.2023.07.002","url":null,"abstract":"<div><p>This review discusses the challenges in drug delivery and the potential benefits of Chronomodulated drug delivery for antiasthmatic drugs. It explores new drugs, personalized medicine approaches, and future directions in asthma treatment, such as immunotherapy and gene therapy. The analysis also discusses the risks of gene therapy for severe asthma and its potential benefits, such as improved medication effectiveness and reduced side effects. Chronomodulated drug delivery, which involves administering medications at specific times to align with the body's natural rhythms, has shown promising results in improving asthma control and reducing the frequency and severity of attacks. For instance, a study found that administering a Chronomodulated antiasthmatic drug in the morning, when lung function is typically at its lowest, significantly improved drug absorption and bioavailability compared to regular drug delivery. This optimized drug delivery not only enhanced the medication's effectiveness but also reduced the need for frequent dosing and minimized side effects, leading to better overall asthma management.</p></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"2 1","pages":"Pages 150-154"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949866X23000564/pdfft?md5=f2183c8ea7838973a597828862261c18&pid=1-s2.0-S2949866X23000564-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80975426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality by design- newer technique for pharmaceutical product development","authors":"Anwar Khan ,&nbsp;Kamran Javed Naquvi ,&nbsp;Md Faheem Haider ,&nbsp;Mohsin Ali Khan","doi":"10.1016/j.ipha.2023.10.004","DOIUrl":"10.1016/j.ipha.2023.10.004","url":null,"abstract":"<div><p>Regulatory bodies are nowadays concerned with pharmaceutical drug products' safety, efficacy, and quality. Quality is the priority of all regulatory bodies, it is a high priority for the triple P factor (patient, pharmacist, and physician). It links pharmaceutical industries and regulatory authorities for designing, manufacturing, and consistently delivering safe and efficient products.</p><p>It mainly focuses on fabricating and designing formulations and manufacturing processes to ensure predefined product quality. It is based on the ICH Guidelines Q8 for pharmaceutical development, Q9 for quality risk management, and Q10 for pharmaceutical quality systems. Some of the important effective elements of QbD are to define the target profile that what is the requirement of the pharmacist, physician, and patient (TPP-QTPP) then measuring the criticality for achieving that target (CQA) and analyzing the risk assessment of variables associated with materials and controlling processes to produce consistent quality over time. The objective of this review is to discuss the concept of Quality by Design and describe its application in pharmaceutical product development.</p></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"2 1","pages":"Pages 122-129"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949866X23000953/pdfft?md5=f841cf29030eede750e751b2b6ca7a7b&pid=1-s2.0-S2949866X23000953-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135762516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cyanobacterial metabolites as novel inhibitors of BACE1 implicated in Alzheimer's disease through in silico approaches","authors":"K Kalaimathi ,&nbsp;S Prabhu ,&nbsp;M. Ayyanar ,&nbsp;K. Shine ,&nbsp;M. Thiruvengadam ,&nbsp;S. Amalraj","doi":"10.1016/j.ipha.2023.10.002","DOIUrl":"10.1016/j.ipha.2023.10.002","url":null,"abstract":"<div><p>Alzheimer's disease (AD) is a complex neurodegenerative disease with a limited number of therapeutic options. β-Secretase 1 (BACE1) is a key enzyme involved in the production of amyloid beta peptides, which are central to AD pathology. Targeting BACE1 has emerged as a promising strategy for the treatment of AD. Therefore, the present study aimed to discover novel drug candidates from cyanobacteria for the treatment of AD through in silico research. In this study, Schrödinger tools were used to study the binding affinities and interactions of cyanobacteria metabolites with BACE1. Almost 120 cyanobacteria metabolites against BACE1 were used for the computational investigation. Ultimately, four marine-derived compounds, namely lyngbyastatin 7, homodolastin 3, lyngbyabellin E1, and symplostatin analogue 4, showed strong binding affinities to the active site of BACE1, forming crucial hydrogen bonds and hydrophobic interactions. The binding energy values of these compounds suggest their potential as BACE1 inhibitors. Furthermore, molecular dynamics simulations confirmed the stability of these ligand-protein complexes over a period of 25 ​ns? Our results provide valuable insights into the potential of lyngbyastatin 7, homodolastin 3, lyngbyabellin E1, and symplostatin analog 4 as effective drugs for inhibiting BACE1. These marine-derived compounds are promising for further in vitro and in vivo studies. The present research suggests that these molecules could offer new avenues for the development of novel therapeutics for the treatment of Alzheimer's disease.</p></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"2 1","pages":"Pages 144-149"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949866X23000862/pdfft?md5=5c0521a0f000b7ce274c89b64103c9dd&pid=1-s2.0-S2949866X23000862-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134978161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Synergistic effects of Woodfordia fruticosa silver nanoparticles accelerating wound healing in Swiss mice in vivo","authors":"Shubhrat Maheshwari","doi":"10.1016/j.ipha.2023.09.005","DOIUrl":"10.1016/j.ipha.2023.09.005","url":null,"abstract":"<div><h3>Background</h3><p>Silver nanoparticles (AgNPs) have gained significant attention in recent years due to their unique physicochemical properties and potential applications in various fields, including medicine, catalysis, and environmental remediation. These nanoparticles possess antimicrobial, anti-inflammatory, and wound-healing properties, making them particularly promising for biomedical applications. The drug <em>Woodfordia fruticosa</em> (<em>Wf</em>) has been traditionally used in folk medicine for its therapeutic properties, such as wound healing, antimicrobial, anti-inflammatory, and antioxidant effects.</p></div><div><h3>Objective</h3><p>The objective of this study was to develop and optimise the synthesis of silver nanoparticles using flower extracts of <em>Woodfordia fruticosa</em> through the distillation extraction method. By employing this technique, the research aimed to successfully create silver nanoparticles from <em>Woodfordia fruticosa</em> gel for the treatment of wounds.</p></div><div><h3>Methods</h3><p>WF flower extracts were prepared by drying the flowers for 14 days and crushing them into a fine powder. The powdered flowers were then sieved through 80-inch sievesThe extracted material was stored at 4 ​°C for further processing. In parallel, a 1 ​mM silver nitrate solution was prepared by dissolving 16.99 ​mg of silver nitrate in 100 ​ml of distilled water. The flower extract and silver nitrate solution were then utilised for the synthesis of silver nanoparticles. The characterization of the synthesised silver nanoparticles was conducted using various techniques, including zeta potential analysis and electron microscopy. These techniques were employed to assess the physicochemical properties, stability, and morphology of the silver nanoparticles. After gel preparation, in vivo wound healing activity was performed.</p></div><div><h3>Result</h3><p>The synthesis of AgNPs using WF flower extracts and silver nitrate solution resulted in the successful formation of nanoparticles. The characterization of the synthesised AgNPs was carried out using various techniques. The zeta potential was found to be −0.283 ​mV, which indicated their stability, and the PDI value was found to be 0.533. These values indicated a stable dispersion of the synthesised AgNPs. Scanning electron microscopy (SEM) showed that nanoparticles have a spherical shape in the range of 5 ​nm.</p></div><div><h3>Conclusion</h3><p>In conclusion, this study successfully developed silver nanoparticles using flower extracts. The developed gel shows that it has wound-healing properties.</p></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"2 1","pages":"Pages 17-27"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949866X23000813/pdfft?md5=9f7b8cb8bb8ba0cf4e7edc1b27d71857&pid=1-s2.0-S2949866X23000813-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136117801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Network pharmacology study of Seleromitrion diffusa (Willd). R. J. Wang and Scutellaria barbata D. Don in the treatment of chronic atrophic gastritis","authors":"Hongmei Luo ,&nbsp;Longzhong Liu ,&nbsp;Jiafeng Zou ,&nbsp;Jiufeng Zhao ,&nbsp;Chengxin Sun ,&nbsp;Shuiping Ou ,&nbsp;Jianwen Yang","doi":"10.1016/j.ipha.2023.10.003","DOIUrl":"10.1016/j.ipha.2023.10.003","url":null,"abstract":"<div><h3>Objective</h3><p>The study aimed to investigate <em>Scutellaria barbata</em> D. Don and <em>Seleromitrion diffusa</em> (Willd). R. J. Wang (HDSB) in the treatment of chronic atrophic gastritis (CAG) by using network pharmacology and literature research.</p></div><div><h3>Methods</h3><p>TCMSP, Uniprot, Drug Bank, OMIM, and GeneCards were used to obtain the active components, targets of <em>Scutellaria barbata</em> D. Don and <em>Seleromitrion diffusa</em> (Willd). R. J. Wang and the disease targets of CAG. Cytoscape 3.9.1 was used to construct a drug network. STRING platform was used to analyze the PPI network, and Metascape was used for functional enrichment analysis and KEGG pathway enrichment analysis.</p></div><div><h3>Results</h3><p>The study found a total of 34 active compounds of HDSB, 153 predicted targets, 970 disease targets, and 46 intersection targets of CAG. And identified a total of 27 prescriptions or proprietary Chinese medicines containing <em>Scutellaria barbata</em> D. Don and <em>Seleromitrion diffusa</em> (Willd). R. J. Wang through literature research and database search, that consists in a 1:1, 1:2, or 2:1 ratio, with a dose range of 15 ​g–300 ​g.</p></div><div><h3>Conclusion</h3><p>The study suggests that <em>Scutellaria barbata</em> D. Don and <em>Seleromitrion diffusa</em> (Willd). R. J. Wang may exert therapeutic effects on chronic atrophic gastritis by acting on JNK, PI3K-Akt, HIF-1, cancer-related and others.</p></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"2 1","pages":"Pages 45-50"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949866X23000941/pdfft?md5=0e2cb4654703f8f9c12531a8d9cb34a4&pid=1-s2.0-S2949866X23000941-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134936289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}